Table S1.

Peak plasma concentration of silymarin in various treatment groups with respect to time

Formulation of silymarin	Cmax (µg/mL)	Tmax (h)
Silymarin powder	0.672±0.141	1.441±0.315
Commercial product	0.726±0.094	1.215±0.217
SGNPs	1.037±0.116*	3.246±0.148*
GSGNPs	1.357±0.128*	4.959±0.235*

Notes: All the results are expressed as mean ± SD.

^*P<0.05 in comparison to silymarin powder treatment.

Abbreviations: SGNPs, silymarin-tethered gold nanoparticles; GSGNPs, SGNPs aggregated in glycogen.